Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published Date:

Abstract

PURPOSE: Consensus molecular subtyping (CMS) of colorectal cancer has potential to reshape the colorectal cancer landscape. We developed and validated an assay that is applicable on formalin-fixed, paraffin-embedded (FFPE) samples of colorectal cancer and implemented the assay in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.

Authors

  • Jeffrey S Morris
    Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
  • Rajyalakshmi Luthra
    Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Yusha Liu
    School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
  • Dzifa Y Duose
    Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wonyul Lee
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Neelima G Reddy
    Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Justin Windham
    NanoString Technologies Inc., Seattle, Washington.
  • Huiqin Chen
    College of Mechanical Engineering, Hangzhou Dianzi University, Hangzhou 310018, China. chenhuiqinfj@126.com.
  • Zhimin Tong
    Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Baili Zhang
    Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wei Wei
    Dept. Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA.
  • Manyam Ganiraju
    Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bradley M Broom
    Department of Bioinformatics and Computational Biology and.
  • Hector A Alvarez
    Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Alicia Mejia
    Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Omkara Veeranki
    Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mark J Routbort
    Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Van K Morris
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • David Menter
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Riham Katkhuda
    Department of Pathology, University of Chicago Medical Center, Chicago, Illinois.
  • Ignacio I Wistuba
    Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Jennifer S Davis
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Scott Kopetz
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dipen M Maru
    Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. dmaru@mdanderson.org.